SCHEMBL7866902

SCHEMBL7866902

CC(O)c1ccc(C(=O)N2CCCc3ccc(-c4ccc5c(c4)OCO5)cc3C2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 7/20 0.51
ALDH1A1 P00352 6/20 0.51
NPC1 O15118 3/20 0.51
TP53 P04637 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
HSD17B10 Q99714 1/20 0.46
RAB9A P51151 2/20 0.45
MAPT P10636 1/20 0.45
PKM P14618 1/20 0.45
RECQL P46063 1/20 0.45
ABCB1 P08183 2/20 0.44
HDAC6 Q9UBN7 1/20 0.43
TSHR P16473 2/20 0.43
USP2 O75604 1/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3749014 0.86 PIK3CA (0.55) HPGDALDH1A1NPC1TP53SMN1; SMN2
SCHEMBL7866781 0.84 ALDH1A1 (0.53) HPGDALDH1A1NPC1TP53SMN1; SMN2
SCHEMBL7867799 0.75 PIK3CA (0.51) HPGDALDH1A1NPC1TP53SMN1; SMN2
SCHEMBL4091888 0.73 GABRA1 (0.49) HPGDALDH1A1NPC1SMN1; SMN2CYP1A2
SCHEMBL13774780 0.73 GABRA1 (0.49) HPGDALDH1A1NPC1SMN1; SMN2CYP1A2
SCHEMBL3750545 0.70 PIK3CA (0.72) PIK3CA
SCHEMBL3756368 0.69 PIK3CA (0.57) HPGDALDH1A1NPC1TP53SMN1; SMN2
SCHEMBL31721651 0.69 ALDH1A1 (0.70) HPGDALDH1A1SMN1; SMN2TSHRLMNA
SCHEMBL3752723 0.68 PIK3CA (0.69) PIK3CA
SCHEMBL5970063 0.67 HPGD (1.00) HPGDALDH1A1NPC1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305093-A1 Inhibitors of mTOR and Methods of Making and Using EXELIXIS, INC. (US) 2010-12-02 US disclosed
US-20100305093-A1 Inhibitors of mTOR and Methods of Making and Using EXELIXIS, INC. (US) 2010-12-02 US disclosed
WO-2010118208-A1 BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER EXELIXIS, INC. (US) 2010-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305093-A1 Inhibitors of mTOR and Methods of Making and Using MTOR, RICTOR, RPTOR HPGD 1748/4885ALDH1A1 3391/4885NPC1 181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.